Clinical trials: Pulmonary Neoplasm
Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer
Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer
The primary objective of this study is to determine the major objective response rate of OSI-774 in participants with unresectable or metastatic bronchioloalveolar cell variant of non-small cell lung cancer.
- Trial name
- NCT00590902
- Testing
- OSI-774: erlotinib, TarcevaTM
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so it can be removed.
- Trial name
- NCT00104728
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma
Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
This randomized phase II trial studies how well pemetrexed disodium with or without erlotinib hydrochloride works in treating patients with stage IIIB-IV or recurrent non-small cell lung cancer.
- Conditions
- Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma
- Trial name
- NCT00950365
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium
- Where
- 5 sites in United States
- Volunteers
- 79 people
- Sponsor
- Albert Einstein College of Medicine
Non-Small Cell Lung Cancer
A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
The main objective of this study was to evaluate the anti-tumor activity of gimistotug (BGB-A445) plus investigational agents in participants with non-small cell lung cancer (NSCLC).
- Trial name
- NCT06029127
- Testing
- Gimistotug, Docetaxel, BGB-15025
- Where
- 18 sites in China, South Korea
- Volunteers
- 35 people
- Sponsor
- BeiGene
Chronic Lymphocytic Leukemia
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
This research study will look at the effects (good or bad) of administering cyclophosphamide, fludarabine, and rituximab. Clinical studies with combination therapy have shown higher response rates than using single drugs, and…
- Trial name
- NCT00280241
- Testing
- Fludarabine, Cyclophosphamide, Rituximab
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Pittsburgh
Carcinoma, Non-small-cell Lung
Study of Tarceva and Targretin in Stage I-II Lung Cancer
The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and Targretin, given in combination before surgical removal of the tumor.
- Trial name
- NCT00125372
- Testing
- erlotinib (Tarceva) and bexarotene (Targretin)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Gastrointestinal Cancer, Lung Cancer
Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients
The goal of this clinical research study is to evaluate the effectiveness of melatonin for the management of poor appetite and weight loss in advanced cancer patients.
- Trial name
- NCT00513357
- Testing
- Melatonin
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00023673
- Testing
- carboplatin, paclitaxel, three-dimensional conformal radiation therapy
- Where
- 41 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Radiation Therapy Oncology Group
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
This is an open-label, dose-escalation/dose-expansion study of INCB059872 in subjects with advanced malignancies. The study will be conducted in 4 parts.
- Trial name
- NCT02712905
- Testing
- INCB059872, all-trans retinoic acid (ATRA), azacitidine
- Where
- 15 sites in United States, Belgium and 1 more
- Volunteers
- 116 people
- Sponsor
- Incyte Corporation
Lung Cancer
Evaluation of Computer-Aided Lung Nodule Detection Software in Thoracic CT for Riverain Technologies LLC
STUDY DESIGN: This is a retrospective, multi-reader, multi-case, (MRMC) randomized reader study. OBJECTIVE: Primary: The primary objective of this clinical study is to prove that a user aided with ClearRead CT InSight (CRCTI) is…
- Trial name
- NCT02440139
- Testing
- ClearRead CT Insight
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Virginia Polytechnic Institute and State University
Non-Small Cell Lung Cancer
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer (NSCLC) participants who had disease recurrence or progression during/after at least one…
- Trial name
- DESTINY-LUNG02 (NCT04644237)
- Testing
- Trastuzumab deruxtecan
- Where
- 50 sites in United States, Australia and 8 more
- Volunteers
- 152 people
- Sponsor
- Daiichi Sankyo
Cancer, Venous Thromboembolism
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients.
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
- Trial name
- CANVAS (NCT02744092)
- Testing
- Rivaroxaban, Apixaban, Edoxaban
- Where
- 151 sites in United States
- Volunteers
- 811 people
- Sponsor
- Alliance Foundation Trials, LLC.
Malignant Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell
Project to Improve Communication About Serious Illness - Pilot Study
This two-year pilot study will test whether a one-page "Jumpstart Form" will affect goals-of-care discussions in the hospital. This form will be provided to clinicians and will include patient-specific information about…
- Conditions
- Malignant Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell, Lung Disease Chronic, Congestive Heart Failure
- Trial name
- PICSI-P (NCT03746392)
- Testing
- Jumpstart Intervention
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of Washington
Breast Cancer, Non Small Cell Lung Cancer
Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression
This study evaluated ADCT-502 in participants with Advanced Solid Tumors with HER2 Expression. Participants participated in a dose-escalation phase (Part 1) and were due to participate in the dose expansion phase (Part 2).
- Conditions
- Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer, Bladder Cancer
- Trial name
- NCT03125200
- Testing
- ADCT-502
- Where
- 5 sites in United States, Belgium
- Volunteers
- 21 people
- Sponsor
- ADC Therapeutics S.A.
Lung Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue near the tumor.
- Trial name
- NCT00551369
- Testing
- SBRT
- Where
- 19 sites in United States
- Volunteers
- 33 people
- Sponsor
- Radiation Therapy Oncology Group
Non-small Cell Lung Cancer, Lung Cancer
Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer
In this research study the investigators are looking for the highest dose of a stereotactic radiation boost that can be given safely.
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, NSCLC
- Trial name
- NCT01222572
- Testing
- Stereotactic boost, Conventional RT, Etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Cancer, Non-small Cell Lung Cancer
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody®-DR5/DR5) in a mixed population of patients with specified solid tumors
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Renal Cell Carcinoma
- Trial name
- NCT03576131
- Testing
- GEN1029 (HexaBody®-DR5/DR5)
- Where
- 6 sites in United States, Spain and 1 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Non-small Cell Lung Cancer
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when given to non-small cell lung cancer (NSCLC)…
- Trial name
- NCT00606502
- Testing
- Pralatrexate, Erlotinib, Vitamin B12
- Where
- 47 sites in United States, Argentina and 4 more
- Volunteers
- 201 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Pharmacokinetics, Solid Tumor
Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
The purpose of this study is to assess the safety and pharmacokinetics of boserolimab (MK-5890) when administered alone and in combination with pembrolizumab (MK-3475) in adults.
- Conditions
- Pharmacokinetics, Solid Tumor, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms
- Trial name
- NCT03396445
- Testing
- Boserolimab, Pembrolizumab, Pemetrexed
- Where
- 18 sites in United States, Chile and 5 more
- Volunteers
- 182 people
- Sponsor
- Merck Sharp & Dohme LLC
Biphasic Mesothelioma, Epithelioid Mesothelioma
Pembrolizumab in Treating Patients With Malignant Mesothelioma
This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum).
- Conditions
- Biphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma, Pleural Biphasic Mesothelioma
- Trial name
- NCT02399371
- Testing
- Pembrolizumab, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Chicago
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.